Rapha Capital Management, LLC https://validator.w3.org/feed/docs/rss2.html Ponce-Deliver Anti-Aging Investor Meeting Rapha Capital Management Media Center About Us Ponce Aurora Appoints Former Estee Lauder Executive as Chief Commercial Officer Ahead of Longevity Product Launches PrintBio Contributes 3D Bioprinting Expertise to ARPA-H PRINT Program for Kidney Bioprinting PrintBio Introduces DynaFlex™ Programmable Surgical Mesh (PSM) at American Hernia Society Meeting 2025 Perseus Senolytix Ponce Aurora Portfolio Eos Senolytix Brent Saunders Appointed as Advisory Board Chairman MD Anderson and Phoenix SENOLYTIX announce cross-licensing agreement of CaspaCIDe™ for cell and gene therapies Phoenix Senolytix PrintBio PrintBio Reorganizes and Expands Leadership Team with Key Commercial and Market Development Appointments Senotherapeutix Rapha Capital PE Life Sciences Fund Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan Arbor Rapha SPAC Pulmatrix and Eos merge to advance gerotherapeutics Contact Us AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107 Events & Presentations Doctors Transplant Ear of Human Cells, Made by 3-D Printer 3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial Popular Science Magazine Names 3D Bio Therapeutics “Best of What’s New – 2022” Grand Award Winner in Health for AuriNovo™ Investor Day Arbor Rapha Capital Bioholdings Corp. I Announces the Separate Trading of its Shares of Class A Common Stock and Redeemable Warrants Commencing December 20, 2021 Rapha Capital BioVentures Fund I Launches DELIVER Therapeutics Inc. with $3 Million Convertible Note Financing DELiver Therapeutics ControlRad, Inc. FIZE Medical Raises $4 Million Series A-1 Financing Arbor Rapha Capital Bioholdings Corp. I Announces Closing of $172.5 Million Initial Public Offering SPACtacular spooky season for Arbor Rapha’s blank check; a $180M Entrada onto Wall Street Arbor Rapha Capital Bioholdings Corp. I Announces Pricing of $150 Million Initial Public Offering Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc. Privacy Policy Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit AsclepiX appoints Dr. Amir Shojaei as Chief Scientific Officer and Executive Vice President, Clinical Development Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma Imagin Medical Announces Appointment of Kayvon Namvar to Board of Directors and Kevin Slawin, M.D. as Board Chairman Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies IMAGIN Medical AsclepiX Therapeutics, Inc. Appoints Robert J. Dempsey as Chief Executive Officer and President Exit History FIZE Medical Secures $30 Million in Series A Funding to Drive Innovations in Fluid Management Technology Culminating in a $14 Million Series A-4 Round Led by Rapha Capital Management IMAGIN MEDICAL Secures New $3 Million Convertible Note Financing Imagin Medical Announces Acquisition of the enCAGE Coil™ Precision Ablation System for Prostate Cancer and a New $7.25M Convertible Note to Finance Its Development